Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Savara (SVRA)
NASDAQ:SVRA
SVRA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.59 - $5.70
Previous CloseN/A
Volume189.20K
Average Volume (3M)858.15K
Market Cap
$461.65M
Enterprise Value$705.50M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.44
Next Earnings
Mar 13, 2025EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.44
Shares Outstanding171,618,940
10 Day Avg. Volume522,648
30 Day Avg. Volume858,146
Standard Deviation0.17
R-Squared0.04
Alpha0.00651
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-5.30
P/FCF Ratio0.00
Enterprise Value/Market Cap1.53
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-15.94
Enterprise Value/Ebitda-7.95
Forecast
1Y Price Target
$8.50Price Target Upside215.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Savara News
PremiumCompany Announcements
Savara Sets 2025 Executive Bonus Targets
PremiumCompany Announcements
Savara Highlights MOLBREEVI’s Potential in Rare Disease Market
---
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyReal-world molgramostim data show increased pulmonary gas transfer, radiologic improvement, improved clinical symptoms and quality of life in patients with autoimmune pulmonary alveolar proteinosis.
Market PotentialThe identification of approximately 1,000 diagnosed aPAP patients in the US before launch largely derisks near-term sales numbers.
Regulatory ApprovalMolbreevi has a breakthrough designation awarded by the FDA, suggesting a priority review.
Bears Say
Financial ConcernsThe need for additional financing poses a potential risk to the commercialization of Molbreevi in the US.
Market ChallengesThe commercial opportunity in aPAP continues to be underappreciated, with a diagnosed U.S. population greater than literature estimates and an expectation for premium rare disease pricing.
Regulatory RisksRisks include regulatory approval, commercializing Molbreevi in the US, and the need for additional financing.
---
Ownership Overview
12.60% Insiders
10.66% Mutual Funds
0.02% Other Institutional Investors
66.88% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SVRA FAQ
What was Savara’s price range in the past 12 months?
Savara lowest stock price was $2.59 and its highest was $5.70 in the past 12 months.
What is Savara’s market cap?
Savara’s market cap is $461.65M.
When is Savara’s upcoming earnings report date?
Savara’s upcoming earnings report date is Mar 13, 2025 which is in 19 days.
How were Savara’s earnings last quarter?
Savara released its earnings results on Nov 12, 2024. The company reported -$0.11 earnings per share for the quarter, missing the consensus estimate of -$0.109 by -$0.001.
Is Savara overvalued?
According to Wall Street analysts Savara’s price is currently Undervalued.
Does Savara pay dividends?
Savara does not currently pay dividends.
What is Savara’s EPS estimate?
Savara’s EPS estimate is -0.11.
How many shares outstanding does Savara have?
Savara has 171,618,940 shares outstanding.
What happened to Savara’s price movement after its last earnings report?
Savara reported an EPS of -$0.11 in its last earnings report, missing expectations of -$0.109. Following the earnings report the stock price went down -5.897%.
Which hedge fund is a major shareholder of Savara?
Currently, no hedge funds are holding shares in SVRA
---
Savara Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.50 (215.99% Upside)
$8.50 (215.99% Upside)
Blogger Sentiment
Bullish
SVRA Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $665.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.4%
Last 30 Days ▼ 8.8%
Last 30 Days ▼ 8.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.19%
12-Months-Change
Fundamentals
Return on Equity
-47.95%
Trailing 12-Months
Asset Growth
31.17%
Trailing 12-Months
Company Description
Savara
Savara, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its products include AeroVanc, Molgradex, GM-CSF, and Aironite. The company was founded on April 27, 2017 and is headquartered in Austin, TX.
---
SVRA Stock 12 Month Forecast
Average Price Target
$8.50
▲(215.99% Upside)
Technical Analysis
Best Analysts Covering SVRA
1 Year
1 Year Success Rate
5/13 ratings generated profit
1 Year Average Return
+2.92%
assigned a buy rating 5 months ago
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 38.46% of your transactions generating a profit, with an average return of +2.92% per trade.
---